💊
Nubeqa
darolutamide
Prostatic Neoplasms, Castration-Resistant
✅ Authorised
✅
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
NUBEQA is indicated for the treatment of adult men with non‑metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).
⚠️ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa